Cometriq (cabozantinib) is already approved for thyroid cancer and is showing promise for late stage kidney cancer.

Cometriq (cabozantinib) is already approved for thyroid cancer and is showing promise for late stage kidney cancer.

Cometriq (cabozantinib) is already approved for thyroid cancer and is showing promise for late stage kidney cancer.

Cabozantinib for Late Stage Kidney Cancer

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers.  The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit CancerGRACE.org for more info.

Science

Medicine

Health & Fitness

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit CancerGRACE.org for more info.

Share Cabozantinib for Late Stage Kidney Cancer

Sign up to save your podcasts

Cabozantinib for Late Stage Kidney Cancer

Cabozantinib for Late Stage Kidney Cancer